AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Seeking Alpha1mon
Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches
Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...